RNS Number : 2295E
Cobra Bio-Manufacturing PLC
16 December 2009
|
For Immediate Release
|
16 December 2009
|
Cobra Biomanufacturing Plc ("Cobra" or "the Group" or "the Company")
Re Announcement by Recipharm AB ("Recipharm")
The Board of Cobra Biomanufacturing Plc, notes the announcement issued today by Recipharm in relation to a mandatory cash offer for the Company at 2.25p per ordinary share.
Trading conditions have remained very challenging with the continued delay in the achievement of contract signatures and as a result the Company does not have sufficient working capital for its current purposes. However, in accordance with the City Code, it is envisaged that Recipharm will loan monies on normal commercial terms to Cobra, in order for Cobra to meet its working capital requirements during the integration of the Recipharm and Cobra businesses.
A further announcement will be made in due course.
For further information, please contact:
|
Cobra Biomanufacturing Plc
|
Tel: +44 (0) 1782 714 181
|
|
Danny Chapchal, Chairman
|
|
|
Simon Saxby, Chief Executive
|
|
|
Peter Coleman, Finance Director
|
|
|
|
|
|
Buchanan Communications
|
Tel: +44 (0) 207 466 5000
|
|
Tim Anderson
|
|
|
|
|
|
Seymour Pierce (NOMAD & Broker)
|
Tel: +44 (0) 20 107 8000
|
|
Chris Howard
|
|
|
Christopher Wren
|
|
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRUNRSRKRRUAAA